Novo Nordisk joined the many pharmaceutical companies pushing back on government-negotiated drug pricing in the United States.

U.S. Steel stock increased more than 16% in reaction to the decision to review the proposed merger with Nippon Steel for a second time.

In at least six letters published in the Seneca Courier-Tribune between January 2021 and March 2024, Hermesch airs his views ...

Long considered resistant to economic downturns, the pharmaceutical industry may face a greater challenge this time around as ...

According to U.S. District Judge Matthew Kacsmaryk, the Biden administration's policy is inconsistent with legislation ...

Shares of U.S. Steel are hitting a 52-week high after President Donald Trump ordered a new national security review of Nippon ...

Compounded versions, made during shortages, have cost less than $200, but regulators plan to stop allowing those soon.